ClinicalTrials.gg
CompletedNCT03859427ARROW2Updated Aug 13, 2024Results posted

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Carfilzomib and Carfilzomib in Relapsed or Refractory Multiple Myeloma, sponsored by Amgen. Completed at 108 sites in 17 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
454
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
8th of 113
454 · median 54
Started
2019
with 11 others
Phase 3
15 of 113
1 open now
Registered
80th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 8th largest by enrollment, is one of 12 that started in 2019, is one of 15 in phase 3, and was the 80th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Bone Marrow Cancer
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 454 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Multiple myeloma with documented relapse or progression after most recent myeloma treatment. Subjects to the most recent are eligible, unless last treatment contained proteasome inhibitor (PI) or lenalidomide and dexamethasone. Refractory is defined as disease that is nonresponsive or progresses within 60 days of last therapy.

Subjects must have at least PR to at least 1 line of prior therapy.

Subjects must have received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation maintenance therapy will be considered as 1 line of therapy).

Prior therapy with a PI or the combination of lenalidomide and dexamethasone are allowed if the patient had at least a PR to the most recent treatment with a PI or lenalidomide and dexamethasone, neither PI or lenalidomide and dexamethasone containing treatment were ceased due to toxicity, the patient has not relapsed within 60 days of discontinuation of the PI or lenalidomide and dexamethasone containing treatment. A history of prior neuropathy is permitted if this was not grade 3, grade 4 or grade 2 with pain and if not resolved within the 14 days before enrollment, is less than or equal to grade 2 without pain. Patients are permitted to have received single agent lenalidomide as maintenance therapy within 60 days of enrollment.

Previous treatment with a lenalidomide and dexamethasone containing regimen is allowed, as long as the subject did not progress during the first 3 months after initiating lenalidomide and dexamethasone containing therapy.

with at least 1 of the following assessed within 21 days prior to randomization:

  • Immunoglobulin G (IgG) multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
  • Immunoglobulin A (IgA), Immunoglobulin D (IgD), Immunoglobulin E (IgE) multiple myeloma: serum M-protein level ≥ 0.5 g/dL
  • Urine M-protein ≥ 200 mg per 24 hours
  • In subjects without measurable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio

Performance Status (ECOG PS) of 0 ≤ 2

Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

Waldenström macroglobulinemia.

Multiple myeloma of Immunoglobulin M (IgM) subtype.

Plasma cell leukemia (> 2.0 × 10\^9 /L circulating plasma cells by standard differential).

Uncontrolled hypertension, defined as a subject whose blood pressure is greater than or equal to 160 mmHg systolic or greater than or equal to 100 mmHg diastolic when taken in accordance with the European Society of Hypertension/European Society of Cardiology 2018 guidelines (Section 12.10; Williams et al, 2018).

Active congestive heart failure ( Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, screening with interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to randomization.

Calculated or measured \< 30 mL/min (calculation must be based on the Cockcroft and Gault formula) within 28 days prior to randomization.

Other exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
454 participants (actual)

Study arms

  • Active comparator
    Carfilzomib once-weekly

    Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using once-weekly carfilzomib 56 mg/m2

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Active comparator
    Carfilzomib twice-weekly

    Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using twice-weekly carfilzomib 27 mg/m2

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.

  • Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.

  • Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent

  • Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)

    ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. The ORR 95% confidence intervals (CIs) were estimated using the Clopper-Pearson method.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

Secondary outcomes

  1. Kaplan-Meier Estimate of Progression-free Survival (PFS) Rate at 12 Months

    PFS rate was defined as the percentage of participants without disease progression or death due to any cause at 12 months. The PFS rate at 12 months was estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 95% CIs were estimated using the method by Kalbfleisch and Prentice (1980). PFS data was censored for participants who met any one of the following: 1. no baseline/no post-baseline disease assessments; 2. starting new anti-myeloma therapy before documentation of progressive disease (PD) or death; 3. PD or death immediately after more than 1 consecutively missed disease assessment visit (PD or death immediately after \> 63 days without disease assessment visit); 4. alive without documentation of PD; 5. lost to follow-up or withdrawn consent.

    Time frame: 12 months

  2. Percentage of Participants Who Reported Convenience as Measured by the Patient-reported Convenience With Carfilzomib-dosing Schedule Question

    Patient-reported convenience was measured by the Patient-reported Convenience with Carfilzomib-dosing Schedule Question. The items in the questionnaire were categorized as 'Convenient', which included responses of 'Very Convenient' and 'Convenient', and 'Inconvenient' which included responses of 'Inconvenient' and 'Very Inconvenient'. The 95% CIs were estimated using the Clopper-Pearson method.

    Time frame: Day 28 of Cycle 4

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs were AEs starting on or after the first dose of any study drug, and up to 30 days of the last dose of any study drug, excluding AEs reported after End of Study date.

    Time frame: Cycle 1 Day 1 up to end of Cycle 12 + 30 days, where each cycle was 28 days; median treatment duration (any study treatment) was 47.00 weeks in the twice-weekly KRd group and 47.14 weeks in the once-weekly KRd group

  4. Time to Response (TTR)

    TTR was defined as the time from randomization to the earliest date when confirmed sCR, CR, VGPR, or PR per IMWG-URC was first achieved.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

  5. Kaplan-Meier Estimate of Duration of Response (DOR)

    For participants who achieved a PR or better, i.e., sCR, CR, VGPR, or PR per IMWG-URC, the DOR was defined as the time from the earliest date when a PR or better was first achieved, and subsequently confirmed, to the earliest date of confirmed PD or death due to any cause. Median DOR was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. For those alive and who had not experienced PD by analysis time, DOR was censored for participants who met any one of the following: 1. no baseline/no post-baseline disease assessments; 2. starting new anti-myeloma therapy before documentation of PD or death; 3. PD or death immediately after more than 1 consecutively missed disease assessment visit (PD or death immediately after \> 63 days without disease assessment visit); 4. alive without documentation of PD; 5. lost to follow-up or withdrawn consent.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

  6. Kaplan-Meier Estimate of Time to Progression (TTP)

    TTP was defined as the duration from randomization for the first documented disease progression per IMWG-UCR. Median TTP was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. TTP was censored for participants who had no confirmed PD at the last non non-evaluable (non-NE), post-baseline disease assessment or the earlier of the following, where applicable: 1. the last non-NE, post-baseline disease assessment prior to start of a new anti-myeloma treatment, or 2. the last non-NE, post-baseline assessment followed \> 63 days later by disease progression; otherwise, at randomization.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

  7. Kaplan-Meier Estimate of Overall Survival (OS)

    OS was defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive or lost to follow-up or withdrawn consent from study by the analysis time were censored at the date on which the participant was last known to be alive.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

  8. Percentage of Participants Who Achieved Minimal Residual Disease Negative Complete Response (MRD[-]CR) by Independent Review Committee (IRC) Per IMWG-URC

    MRD\[-\]CR was defined as achievement of CR or better by IRC per IMWG-URC and achievement of MRD negativity as assessed by next generation sequencing method at a 10\^-5 threshold over the duration of the study. The 95% CIs for percentages were estimated using the Clopper-Pearson method.

    Time frame: Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.

  9. Percentage of Participants With Minimal Residual Disease Negativity (MRD[-]) by IRC Per IMWG-URC at 12 Months

    The percentage of participants with achievement of MRD\[-\] at 12 months (± 4 weeks) from randomization, as assessed by next generation sequencing method at a 10\^-5 threshold. MRD negativity results from BM samples obtained at 8 to 13 months from randomization and prior to new anti-myeloma therapy or disease progression were considered in the calculation. The 95% CIs for percentages were estimated using the Clopper-Pearson method.

    Time frame: Cycle 1 Day 1 up to 12 months (cycle = 28 days)

  10. Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)-Core 30 (C30) Physical Functioning Scale

    The QLQ-C30 physical function is one of the functional domains of the EORTC QLQ-C30 self-reported instrument and the physical functioning score score ranges from 0-100 points, with 100 points indicating the best possible functioning. A positive change from baseline indicated an improvement in functioning.

    Time frame: Baseline (Cycle 1 Day 1), Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)

  11. Change From Baseline in EORTC QLQ-C30 Role Functioning Scale

    The QLQ-C30 role function is one of the functional domains of the EORTC QLQ-C30 self-reported instrument and the role functioning score ranges from 0-100 points, with 100 points indicating the best possible functioning. A positive change from baseline indicated an improvement in functioning.

    Time frame: Baseline (Cycle 1 Day 1), Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)

  12. Patient-reported Treatment Satisfaction as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ)

    The CTSQ measures treatment satisfaction in individuals with cancer and includes a domain for satisfaction with therapy. The satisfaction with therapy scores ranges from 0 to 100 points, with 100 points indicating greatest satisfaction. Analysis was based on ANCOVA model. The dependent variable of the models were the scale scores measured at each visit. The model included effects of intercept, scale score measured at cycle 2 day 1 visit, treatment arm, and randomization stratification factors.

    Time frame: Cycle 5 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)

08

Results

Posted Apr 18, 2024

Participant flow

Participants were enrolled at 80 study centers in Europe, Japan, and the United States, and participated from 08 May 2019 to 31 March 2023.

Participant flow — Overall Study
MilestoneTwice-weekly Kyprolis (Carfilzomib) + Lenalidomide + Dexamethsone (KRd) 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Started226228
Received carfilzomib226228
Completed 12 cycles carfilzomib152150
Received lenalidomide226228
Received dexamethasone226228
Safety population231223
Completed197191
Not completed2937
Withdrew: Withdrawal by subject47
Withdrew: Decision by sponsor03
Withdrew: Lost to follow-up32
Withdrew: Death2225

Outcome measures

PrimaryOverall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)

ORR was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. The ORR 95% confidence intervals (CIs) were estimated using the Clopper-Pearson method.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
percentage of participantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)86.3 (81.1 to 90.5)82.5 (76.9 to 87.2)
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Synthesis approach · p = 0.0666 (P-value (2.5% significance level) of the non-inferiority test via the synthesis approach (FDA, 2016) for non-inferiority comparison of ORR between treatment arms.) · Risk ratio (rr): 0.954 · 95% CI 0.882 to 1.032Risk ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.
SecondaryKaplan-Meier Estimate of Progression-free Survival (PFS) Rate at 12 Months

PFS rate was defined as the percentage of participants without disease progression or death due to any cause at 12 months. The PFS rate at 12 months was estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 95% CIs were estimated using the method by Kalbfleisch and Prentice (1980). PFS data was censored for participants who met any one of the following: 1. no baseline/no post-baseline disease assessments; 2. starting new anti-myeloma therapy before documentation of progressive disease (PD) or death; 3. PD or death immediately after more than 1 consecutively missed disease assessment visit (PD or death immediately after \> 63 days without disease assessment visit); 4. alive without documentation of PD; 5. lost to follow-up or withdrawn consent.

Time frame:
12 months
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Progression-free Survival (PFS) Rate at 12 Months
percentage of participantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Kaplan-Meier Estimate of Progression-free Survival (PFS) Rate at 12 Months79.7 (73.6 to 84.6)80.7 (74.7 to 85.4)
SecondaryPercentage of Participants Who Reported Convenience as Measured by the Patient-reported Convenience With Carfilzomib-dosing Schedule Question

Patient-reported convenience was measured by the Patient-reported Convenience with Carfilzomib-dosing Schedule Question. The items in the questionnaire were categorized as 'Convenient', which included responses of 'Very Convenient' and 'Convenient', and 'Inconvenient' which included responses of 'Inconvenient' and 'Very Inconvenient'. The 95% CIs were estimated using the Clopper-Pearson method.

Time frame:
Day 28 of Cycle 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Reported Convenience as Measured by the Patient-reported Convenience With Carfilzomib-dosing Schedule Question
percentage of participantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Percentage of Participants Who Reported Convenience as Measured by the Patient-reported Convenience With Carfilzomib-dosing Schedule Question80.5 (74.8 to 85.5)81.6 (75.9 to 86.4)
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Odds ratio (or): 1.049 · 95% CI 0.653 to 1.683Odds ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs were AEs starting on or after the first dose of any study drug, and up to 30 days of the last dose of any study drug, excluding AEs reported after End of Study date.

Time frame:
Cycle 1 Day 1 up to end of Cycle 12 + 30 days, where each cycle was 28 days; median treatment duration (any study treatment) was 47.00 weeks in the twice-weekly KRd group and 47.14 weeks in the once-weekly KRd group
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Number of Participants With Treatment-emergent Adverse Events (TEAEs)219209
SecondaryTime to Response (TTR)

TTR was defined as the time from randomization to the earliest date when confirmed sCR, CR, VGPR, or PR per IMWG-URC was first achieved.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Median · months
Time to Response (TTR)
monthsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Time to Response (TTR)1.0 (1 to 12)1.0 (1 to 10)
SecondaryKaplan-Meier Estimate of Duration of Response (DOR)

For participants who achieved a PR or better, i.e., sCR, CR, VGPR, or PR per IMWG-URC, the DOR was defined as the time from the earliest date when a PR or better was first achieved, and subsequently confirmed, to the earliest date of confirmed PD or death due to any cause. Median DOR was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. For those alive and who had not experienced PD by analysis time, DOR was censored for participants who met any one of the following: 1. no baseline/no post-baseline disease assessments; 2. starting new anti-myeloma therapy before documentation of PD or death; 3. PD or death immediately after more than 1 consecutively missed disease assessment visit (PD or death immediately after \> 63 days without disease assessment visit); 4. alive without documentation of PD; 5. lost to follow-up or withdrawn consent.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Median · months
Kaplan-Meier Estimate of Duration of Response (DOR)
monthsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Kaplan-Meier Estimate of Duration of Response (DOR)NA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimate of Time to Progression (TTP)

TTP was defined as the duration from randomization for the first documented disease progression per IMWG-UCR. Median TTP was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. TTP was censored for participants who had no confirmed PD at the last non non-evaluable (non-NE), post-baseline disease assessment or the earlier of the following, where applicable: 1. the last non-NE, post-baseline disease assessment prior to start of a new anti-myeloma treatment, or 2. the last non-NE, post-baseline assessment followed \> 63 days later by disease progression; otherwise, at randomization.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Median · months
Kaplan-Meier Estimate of Time to Progression (TTP)
monthsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Kaplan-Meier Estimate of Time to Progression (TTP)NA (NA to NA)NA (NA to NA)
SecondaryKaplan-Meier Estimate of Overall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive or lost to follow-up or withdrawn consent from study by the analysis time were censored at the date on which the participant was last known to be alive.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Median · months
Kaplan-Meier Estimate of Overall Survival (OS)
monthsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Kaplan-Meier Estimate of Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved Minimal Residual Disease Negative Complete Response (MRD[-]CR) by Independent Review Committee (IRC) Per IMWG-URC

MRD\[-\]CR was defined as achievement of CR or better by IRC per IMWG-URC and achievement of MRD negativity as assessed by next generation sequencing method at a 10\^-5 threshold over the duration of the study. The 95% CIs for percentages were estimated using the Clopper-Pearson method.

Time frame:
Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Residual Disease Negative Complete Response (MRD[-]CR) by Independent Review Committee (IRC) Per IMWG-URC
percentage of participantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Percentage of Participants Who Achieved Minimal Residual Disease Negative Complete Response (MRD[-]CR) by Independent Review Committee (IRC) Per IMWG-URC18.1 (13.3 to 23.8)21.5 (16.3 to 27.4)
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Odds ratio (or): 1.235 · 95% CI 0.775 to 1.970Odds ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.
SecondaryPercentage of Participants With Minimal Residual Disease Negativity (MRD[-]) by IRC Per IMWG-URC at 12 Months

The percentage of participants with achievement of MRD\[-\] at 12 months (± 4 weeks) from randomization, as assessed by next generation sequencing method at a 10\^-5 threshold. MRD negativity results from BM samples obtained at 8 to 13 months from randomization and prior to new anti-myeloma therapy or disease progression were considered in the calculation. The 95% CIs for percentages were estimated using the Clopper-Pearson method.

Time frame:
Cycle 1 Day 1 up to 12 months (cycle = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease Negativity (MRD[-]) by IRC Per IMWG-URC at 12 Months
percentage of participantsTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Percentage of Participants With Minimal Residual Disease Negativity (MRD[-]) by IRC Per IMWG-URC at 12 Months18.1 (13.3 to 23.8)18.9 (14.0 to 24.6)
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Odds ratio (or): 1.060 · 95% CI 0.657 to 1.711Odds ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)-Core 30 (C30) Physical Functioning Scale

The QLQ-C30 physical function is one of the functional domains of the EORTC QLQ-C30 self-reported instrument and the physical functioning score score ranges from 0-100 points, with 100 points indicating the best possible functioning. A positive change from baseline indicated an improvement in functioning.

Time frame:
Baseline (Cycle 1 Day 1), Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ)-Core 30 (C30) Physical Functioning Scale
Score on a scaleTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Cycle 3 Day 1-2.76 ± 16.84-0.77 ± 14.95
Cycle 5 Day 1-2.65 ± 15.760.26 ± 15.59
Cycle 7 Day 1-0.82 ± 16.590.17 ± 14.62
Cycle 9 Day 1-1.05 ± 15.592.03 ± 14.75
Cycle 12 Day 1-1.89 ± 15.151.06 ± 15.63
Safety Follow-up-1.55 ± 16.312.11 ± 18.27
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Least squares (ls) mean difference: 2.53 · 95% CI 0.38 to 4.69Analysis was based on repeated measures analysis of covariance (ANCOVA) model, including arm, baseline scale score, randomization stratification factors and visit as repeated measure.
SecondaryChange From Baseline in EORTC QLQ-C30 Role Functioning Scale

The QLQ-C30 role function is one of the functional domains of the EORTC QLQ-C30 self-reported instrument and the role functioning score ranges from 0-100 points, with 100 points indicating the best possible functioning. A positive change from baseline indicated an improvement in functioning.

Time frame:
Baseline (Cycle 1 Day 1), Cycle 3 Day 1, Cycle 5 Day 1, Cycle 7 Day 1, Cycle 9 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)
Reported as:
Mean · Score on a scale
Change From Baseline in EORTC QLQ-C30 Role Functioning Scale
Score on a scaleTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Cycle 3 Day 1-4.30 ± 26.16-2.47 ± 24.81
Cycle 5 Day 1-2.67 ± 25.77-3.11 ± 24.32
Cycle 7 Day 1-3.29 ± 26.191.76 ± 24.34
Cycle 9 Day 1-0.88 ± 23.242.70 ± 24.90
Cycle 12 Day 1-0.25 ± 23.211.64 ± 28.97
Safety Follow-up-2.28 ± 24.733.68 ± 26.24
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Ls mean difference: 1.73 · 95% CI -1.26 to 4.72Analysis was based on ANCOVA model, including arm, baseline scale score, randomization stratification factors and visit as repeated measure.
SecondaryPatient-reported Treatment Satisfaction as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ)

The CTSQ measures treatment satisfaction in individuals with cancer and includes a domain for satisfaction with therapy. The satisfaction with therapy scores ranges from 0 to 100 points, with 100 points indicating greatest satisfaction. Analysis was based on ANCOVA model. The dependent variable of the models were the scale scores measured at each visit. The model included effects of intercept, scale score measured at cycle 2 day 1 visit, treatment arm, and randomization stratification factors.

Time frame:
Cycle 5 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)
Reported as:
Least squares mean · Score on a scale
Patient-reported Treatment Satisfaction as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Score on a scaleTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
Cycle 5 Day 175.73 ± 1.7875.47 ± 1.76
Cycle 12 Day 178.39 ± 2.4077.91 ± 2.40
Safety follow-up74.55 ± 2.5875.99 ± 2.49
Statistical analysis
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Ls mean difference: -0.26 · 95% CI -2.54 to 2.03Treatment difference at Cycle 5
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Ls mean difference: -0.48 · 95% CI -3.24 to 2.28Treatment difference at Cycle 12
  • Twice-weekly KRd 20/27 mg/m^2 vs Once-weekly KRd 20/56 mg/m^2 · Ls mean difference: 1.44 · 95% CI -1.69 to 4.58Treatment difference at safety follow-up

Adverse events

Collected over All-cause mortality was collected from enrollment to End of Study; median study duration was 12.0 months. AEs were collected from first dose of study drug to last dose of study drug + 30 days; median treatment duration (any study treatment) was 11.8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Twice-weekly KRd 20/27 mg/m^222/226 (9.7%)75/231 (32.5%)190/231 (82.3%)
Once-weekly KRd 20/56 mg/m^226/228 (11.4%)84/223 (37.7%)182/223 (81.6%)
Most frequent serious events
Showing 10 of 114
Most frequent serious events
EventTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
PneumoniaInfections and infestations9/23112/223
COVID-19 pneumoniaInfections and infestations11/2318/223
COVID-19Infections and infestations3/2316/223
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/2311/223
DeathGeneral disorders0/2313/223
SepsisInfections and infestations1/2313/223
Acute kidney injuryRenal and urinary disorders3/2311/223
Deep vein thrombosisVascular disorders3/2312/223
Febrile neutropeniaBlood and lymphatic system disorders0/2312/223
ThrombocytopeniaBlood and lymphatic system disorders2/2312/223
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTwice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2
NeutropeniaBlood and lymphatic system disorders73/23165/223
AnaemiaBlood and lymphatic system disorders55/23156/223
HypertensionVascular disorders56/23148/223
ThrombocytopeniaBlood and lymphatic system disorders31/23146/223
DiarrhoeaGastrointestinal disorders43/23142/223
Upper respiratory tract infectionInfections and infestations33/23132/223
FatigueGeneral disorders29/23124/223
PyrexiaGeneral disorders27/23123/223
AstheniaGeneral disorders13/23126/223
ConstipationGastrointestinal disorders17/23123/223

Baseline characteristics

Age, Continuous
Age, Continuous(years)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Mean64.0 ± 8.263.7 ± 8.463.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Female100118218
Male126110236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Hispanic or Latino8816
Not Hispanic or Latino213215428
Unknown or Not Reported5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
American Indian or Alaska Native000
Asian91221
Black or African American112
Native Hawaiian or Other Pacific Islander000
White209209418
Other7613
Original ISS Stage at Study Entry
Original ISS Stage at Study Entry(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Stage 1 or 2201201402
Stage 3252752
Prior Lenalidomide Treatment
Prior Lenalidomide Treatment(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Yes7985164
No147143290
Prior Proteasome Inhibitor Treatment
Prior Proteasome Inhibitor Treatment(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Yes218214432
No81422
Prior Anti-CD38 Treatment
Prior Anti-CD38 Treatment(Participants)Twice-weekly KRd 20/27 mg/m^2Once-weekly KRd 20/56 mg/m^2Total
Yes172138
No209207416
09

Study locations

108 sites
  • Robert A Moss Oncology
    Fountain Valley, California 92708, United States
  • Rocky Mountain Cancer Centers Denver Midtown
    Denver, Colorado 80218, United States
  • Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
    Plainville, Connecticut 06062, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Advocate Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Texas Oncology-Denton
    Denton, Texas 76201, United States
  • US Oncology Research Investigational Products Center
    Fort Worth, Texas 76177, United States
  • Oncology Consultants PA
    Houston, Texas 77030, United States
  • Texas Oncology
    San Antonio, Texas 78229, United States
  • United States Oncology Regulatory Affairs Corporate Office
    The Woodlands, Texas 77380, United States
  • Universitaetsklinikum Salzburg
    Salzburg, 5020, Austria
  • University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • Specialized Hospital for Active Treatment of Hematology Diseases EAD
    Sofia, 1756, Bulgaria
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Helsingin Yliopistollinen Keskussairaala
    Helsinki, 00290, Finland
  • Oulun Yliopistollinen Sairaala
    Oulu, 90220, Finland
  • Turun Yliopistollinen Keskussairaala
    Turku, 20521, Finland
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44000, France
  • Centre Hospitalier Universitaire Archet 2
    Nice cedex 3, 06202, France
  • Hopital Saint Louis
    Paris, 75010, France
  • Hopital Pitie-Salpetriere
    Paris, 75013, France
  • Centre Hospitalier Lyon Sud
    Pierre-Benite, 69495, France
  • Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie
    Poitiers Cedex, 86021, France
  • Centre Hospitalier Universitaire de Rennes
    Rennes, 35033, France
  • Institut de Cancerologie Strasbourg
    Strasbourg, 67033, France
  • Institut Universitaire du Cancer Toulouse Oncopole
    Toulouse cedex 9, 31059, France
  • Centre Hospitalier Universitaire de Nancy - Hopital de Brabois
    Vandoeuvre les Nancy Cedex, 54511, France
  • Charité, Universitätsklinikum Berlin, Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitatsklinikum Koln
    Köln, 50924, Germany
  • Johannes Gutenberg Universitaet Mainz
    Mainz, 55131, Germany
  • University Hospital of Alexandroupolis
    Alexandroupoli, 68100, Greece
  • General Hospital Evangelismos
    Athens, 10676, Greece
  • Agios Savvas Anticancer Hospital
    Athens, 115 22, Greece
  • 251 General Airforce Hospital
    Athens, 11525, Greece
  • Alexandra Hospital
    Athens, 11528, Greece
  • Metropolitan Hospital
    Athens, 18547, Greece
  • General University Hospital of Patras Panagia i Voithia
    Patra, 26504, Greece
  • Theagenion Cancer Hospital of Thessaloniki
    Thessaloniki, 54007, Greece
  • General Hospital of Thessaloniki Georgios Papanikolaou
    Thessaloniki, 57010, Greece
  • Nagoya City University Hospital
    Nagoya-shi, Aichi 467-8602, Japan
  • Toyohashi Municipal Hospital
    Toyohashi-shi, Aichi 441-8570, Japan
  • Tesshokai Kameda General Hospital
    Kamogawa-shi, Chiba 296-8602, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka-shi, Fukuoka 811-1395, Japan
  • Ogaki Municipal Hospital
    Ogaki-shi, Gifu 503-8502, Japan
  • National Hospital Organization Shibukawa Medical Center
    Shibukawa-shi, Gunma 377-0280, Japan
  • Japanese Red Cross Society Himeji Hospital
    Himeji-shi, Hyogo 670-8540, Japan
  • Hyogo College of Medicine Hospital
    Nishinomiya-shi, Hyogo 663-8501, Japan
  • Hitachi Ltd Hitachi General Hospital
    Hitachi-shi, Ibaraki 317-0077, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto-shi, Kyoto 602-8566, Japan
  • National Hospital Organization Sendai Medical Center
    Sendai-shi, Miyagi 983-8520, Japan
  • Niigata Cancer Center Hospital
    Niigata-shi, Niigata 951-8566, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama-shi, Okayama 701-1192, Japan
  • Japanese Red Cross Osaka Hospital
    Osaka-shi, Osaka 543-8555, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka 589-8511, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565-0871, Japan
  • Saitama Medical Center
    Kawagoe-shi, Saitama 350-8550, Japan
  • Tochigi Cancer Center
    Utsunomiya-shi, Tochigi 320-0834, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Koto-ku, Tokyo 135-8550, Japan
  • Japanese Red Cross Medical Center
    Shibuya-ku, Tokyo 150-8935, Japan
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics Public Institution
    Kaunas, 50009, Lithuania
  • Vilnius University Hospital Santaros Clinic Public Institution
    Vilnius, 08661, Lithuania
  • VU Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Gelre Ziekenhuizen
    Apeldoorn, 7334 DZ, Netherlands
  • Spaarne Gasthuis
    Hoofddorp, 2134 TM, Netherlands
  • Fundeni Clinical Institute
    Bucharest, 022328, Romania
  • Institutul Clinic Fundeni
    Bucharest, 022328, Romania
  • Spitalul Clinic Coltea
    Bucharest, 030171, Romania
  • Spitalul Universitar de Urgenta Bucuresti
    Bucharest, 050098, Romania
  • Spitalul Clinic Colentina
    Bucuresti, 020125, Romania
  • Institutul Oncologic Prof Dr Ion Chiricuta
    Cluj-Napoca, 400015, Romania
  • Institutul Regional de Oncologie Iasi
    Iasi, 700483, Romania
  • Spitalul Clinic Dr Gavril Curteanu Oradea
    Oradea, 410469, Romania
  • Spitalul Clinic Judetean de Urgenta Sibiu
    Sibiu, 550245, Romania
  • Spitalul Clinic Municipal de Urgenta Timisoara
    Timisoara, 300079, Romania
  • Regional Clinical Hospital
    Krasnoyarsk, 660022, Russian Federation
  • Moscow State Budget Healthcare Institution City clinical Hospital 52 of Moscow Healthcare Department
    Moscow, 123182, Russian Federation
  • SBHI of Moscow city City clinical hospital na S P Botkin of Moscow city Healthcare department
    Moscow, 125284, Russian Federation
  • SBHI of Republic of Karelia Republic Hosiptal n a V A Baranov
    Petrozavodsk, 185019, Russian Federation
  • Federal centre of heart, blood and endocrinology Almazova
    Saint Petersburg, 197341, Russian Federation
  • State Budget Educational Institution of High Professional Skills Samara State Medical University
    Samara, 443079, Russian Federation
  • Univerzitna nemocnica Bratislava, Nemocnica sv Cyrila a Metoda
    Bratislava, 851 07, Slovakia
  • Hospital Universitari Son Espases
    Palma de Mallorca, Baleares 07010, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, Castilla León 37007, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Cataluña 08916, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Cataluña 08036, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Falu Lasarett
    Falun, 791 82, Sweden
  • Sahlgrenska Universitetssjukhuset
    Goteborg, 413 45, Sweden
  • Hallands Sjukhus Halmstad
    Halmstad, 301 85, Sweden
  • Sunderby Sjukhus
    Lulea, 971 80, Sweden

Showing the first 100 of 108 sites across 17 countries. Choose a country and city above to see the rest.

10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Mar 2023, 46 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 46 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2019
First posted
Mar 1, 2019
StartActual
May 8, 2019
Primary completionActual
Mar 31, 2023
CompletionActual
Mar 31, 2023
Results first posted
Apr 18, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03859427
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
May 8, 2019
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Results posted
Apr 18, 2024
Last update
Aug 13, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Lenalidomide · Dexamethasone

Start the discussion